Hepatitis B en pacientes con hepatitis C tratados con agentes antivirales directos
- Maria Luisa Gutierrez Garcia 1
- María Luisa Manzano Alonso 2
- Juan Ángel Ferrer Rosique 1
- Raquel Muñoz Gómez 2
- Sonia Alonso López 1
- Inmaculada Fernández 2
- Conrado M. Fernández Rodriguez 1
- 1 Hospital Universitario Fundación Alcorcón. Alcorcón, Madrid
- 2 Hospital Doce de Octubre. Madrid
ISSN: 2340-416, 1130-0108
Année de publication: 2019
Volumen: 111
Número: 2
Pages: 129-133
Type: Article
D'autres publications dans: Revista Española de Enfermedades Digestivas
Résumé
Introduction: cases of hepatitis B virus (HBV) reactivation have been reported in patients with hepatitis C virus (HCV) treated with direct antiviral agents (DAA). Objectives and methods: the main objectives of the present study are: a) to determine the prevalence of HBV/HCV coinfection in HCV patients treated with DAAs in the Autonomous Community of Madrid (CM) and also to determine the incidence and clinical relevance of HBV reactivation; and b) to determine the HBV screening rates in HCV patients in our region. For that purpose, 1,337 HCV patients were consecutively treated with DAAs in two hospitals located in South CM between January 2015 and June 2017. Results: nine of the 1,337 (0.67%) participants were HBsAg positive and 356 (26.6%) had previous HBV infection markers. Two of the four (50%) HBsAg positive patients with untreated HBV developed a virological reactivation, but not a biochemical reaction. Of the 356 patients with previous HBV infection markers, all had normal transaminases at the end of treatment and during follow-up. The HBV screening rate amounted to 92.9% of the cohort. Conclusions: the prevalence of HBV (HBsAg positive) infection in patients with chronic hepatitis C in the southern area of the CM is low. HBV reactivation in HBsAg positive patients treated with DAAs is common, although without clinical relevance. In our region, there is a high rate of HBV screening in patients with HCV that are likely treated with DAAs.